PT-141 is another name associated with bremelanotide. In the United States, Vyleesi is an approved bremelanotide injection for a defined form of hypoactive sexual desire disorder in premenopausal women. Its prescribing information specifies the product, population and important restrictions. That approval does not automatically apply to a nasal spray bearing the same molecule name. Vyleesi full prescribing information

The route is part of the evidence

Changing delivery route can change exposure, variability and local effects. A study of one formulation does not establish the performance of a different formulation or delivery device. Even a genuine active ingredient would not resolve those questions by itself.

For a nasal product, a scientific review would need to examine the formulation, delivery characteristics, stability and clinical evidence for that exact product. FDA's nasal-spray guidance treats formulation and manufacturing controls as substantive development questions, not packaging details. FDA nasal spray chemistry manufacturing and controls guidance

Read the clinical boundaries

The Vyleesi label does not establish treatment of every sexual-function concern, use in every population or general sexual enhancement. It also includes clinically important precautions, including cardiovascular considerations, and requires appropriate medical assessment. Those boundaries should remain clear in educational coverage.

A consumer testimonial about a nasal spray cannot establish equivalence to the approved injection. Nor can an analytical purity report show that the spray has demonstrated clinical benefit or an acceptable safety profile.

AXON's conclusion is formulation-specific: bremelanotide has an approved injectable product, while claims for an intranasal product require their own evidence and current regulatory assessment. This article provides no preparation, administration or dosing instructions. A sexual-medicine specialist and regulatory reviewer should evaluate any proposed product-specific claim before publication.